Company
Headquarters: Sydney, NSW, Australia
Employees: 41
CEO: Dr. Colin David Biggin Ph.D.
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
| Last Financial Reports Date | June 30, 2023 |
| Revenue TTM | A$9.5 M |
| EBITDA | A$-32,623,064 |
| Gross Profit TTM | A$0 |
| Profit Margin | 0.00% |
| Operating Margin | -335.86% |
| Quarterly Revenue Growth | -5.50% |
Clarity Pharmaceuticals Ltd has the following listings and related stock indices.
Stock: ASX: CU6 wb_incandescent